10.1038/s41391-021-00395-4 - Overall survival and adverse events a...

This document has been corrected

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

10.1038/s41391-021-00395-4

Published Online: 2021-05-30

Journal: Prostate Cancer and Prostatic Diseases•Publisher: Springer Science and Business Media LLC

Authors: Alberto Briganti•Christoph Würnschimmel•Claudia Collà Ruvolo•Derya Tilki•Felix K. H. Chun•Francesco Montorsi•Fred Saad•Luigi Nocera•Luis A. Kluth•Markus Graefen•Mike Wenzel•Philipp Mandel•Pierre I. Karakiewicz•Shahrokh F. Shariat•Zhe Tian

This document has been corrected

10.1038/s41391-021-00395-4

Published Online: 2021-05-30

Journal: Prostate Cancer and Prostatic Diseases

NOW

2023-03-10•Correction

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

10.1038/s41391-023-00656-4

* information provided by CrossRef

2023-03-10•Correction

10.1038/s41391-023-00656-4

* information provided by CrossRef

2021-05-30•Published

2023-03-10•Correction

10.1038/s41391-023-00656-4

* information provided by CrossRef

This document has been corrected

10.1038/s41391-021-00395-4

Published Online: 2021-05-30

Journal: Prostate Cancer and Prostatic Diseases•Publisher: Springer Science and Business Media LLC